PROCEPT BioRobotics Co. (NASDAQ:PRCT) Shares Acquired by Sentry Investment Management LLC

Sentry Investment Management LLC boosted its position in PROCEPT BioRobotics Co. (NASDAQ:PRCT) by 215.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 4,718 shares of the company’s stock after buying an additional 3,223 shares during the quarter. Sentry Investment Management LLC’s holdings in PROCEPT BioRobotics were worth $380,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. KRS Capital Management LLC increased its stake in PROCEPT BioRobotics by 0.5% during the fourth quarter. KRS Capital Management LLC now owns 46,455 shares of the company’s stock valued at $3,741,000 after purchasing an additional 225 shares during the last quarter. KBC Group NV boosted its holdings in shares of PROCEPT BioRobotics by 32.6% in the 3rd quarter. KBC Group NV now owns 1,531 shares of the company’s stock valued at $123,000 after buying an additional 376 shares during the period. Raleigh Capital Management Inc. acquired a new position in shares of PROCEPT BioRobotics in the 4th quarter valued at about $32,000. Nisa Investment Advisors LLC grew its position in shares of PROCEPT BioRobotics by 178.3% during the 3rd quarter. Nisa Investment Advisors LLC now owns 1,113 shares of the company’s stock valued at $89,000 after buying an additional 713 shares during the last quarter. Finally, IFP Advisors Inc acquired a new stake in PROCEPT BioRobotics during the fourth quarter worth about $58,000. Institutional investors and hedge funds own 89.46% of the company’s stock.

PROCEPT BioRobotics Stock Down 3.7 %

PRCT opened at $62.71 on Wednesday. The stock’s 50 day moving average price is $75.53 and its 200 day moving average price is $80.02. The company has a debt-to-equity ratio of 0.21, a current ratio of 6.02 and a quick ratio of 5.07. The stock has a market cap of $3.27 billion, a P/E ratio of -32.16 and a beta of 1.03. PROCEPT BioRobotics Co. has a 12 month low of $45.20 and a 12 month high of $103.81.

PROCEPT BioRobotics (NASDAQ:PRCT) last issued its quarterly earnings results on Tuesday, February 25th. The company reported ($0.35) EPS for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.01). The business had revenue of $68.24 million for the quarter, compared to analyst estimates of $66.79 million. PROCEPT BioRobotics had a negative net margin of 50.07% and a negative return on equity of 38.57%. As a group, research analysts predict that PROCEPT BioRobotics Co. will post -1.75 earnings per share for the current year.

Insider Transactions at PROCEPT BioRobotics

In other PROCEPT BioRobotics news, EVP Alaleh Nouri sold 28,092 shares of the company’s stock in a transaction that occurred on Wednesday, December 4th. The stock was sold at an average price of $97.13, for a total value of $2,728,575.96. Following the completion of the sale, the executive vice president now directly owns 52,472 shares in the company, valued at $5,096,605.36. This represents a 34.87 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Reza Zadno sold 26,423 shares of PROCEPT BioRobotics stock in a transaction on Wednesday, December 4th. The shares were sold at an average price of $97.22, for a total value of $2,568,844.06. Following the transaction, the chief executive officer now owns 152,762 shares in the company, valued at approximately $14,851,521.64. This trade represents a 14.75 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 17.40% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the company. Wells Fargo & Company restated an “overweight” rating and issued a $112.00 target price on shares of PROCEPT BioRobotics in a research note on Tuesday, December 3rd. Morgan Stanley initiated coverage on PROCEPT BioRobotics in a research report on Monday, December 2nd. They set an “overweight” rating and a $105.00 price objective for the company. Jefferies Financial Group began coverage on PROCEPT BioRobotics in a research note on Thursday, November 14th. They set a “hold” rating and a $95.00 price objective for the company. Finally, Truist Financial reissued a “buy” rating and set a $105.00 price target (up previously from $95.00) on shares of PROCEPT BioRobotics in a report on Wednesday, October 30th. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $97.86.

About PROCEPT BioRobotics

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).